Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | UGCG | Q16739 | 2/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509418 | 1.00 | MEN1 (0.46) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL21458948 | 1.00 | MEN1 (0.46) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL21068940 | 0.99 | MEN1 (0.47) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL21068789 | 0.97 | MEN1 (0.49) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL27179372 | 0.97 | MEN1 (0.49) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL24574174 | 0.97 | MEN1 (0.49) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL20305533 | 0.97 | MEN1 (0.49) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL27031980 | 0.97 | KDM4C (0.47) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL20305765 | 0.96 | MEN1 (0.51) | MEN1KMT2AKDM4CFOXM1EPHX2 | |
| SCHEMBL22787074 | 0.96 | MEN1 (0.51) | MEN1KMT2AKDM4CFOXM1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885KDM4C 2519/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885KDM4C 2519/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | MEN1 3384/4885KMT2A 1095/4885KDM4C 1743/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | MEN1 2058/4885KMT2A 1443/4885KDM4C 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.